Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Helix BioPharma Corp.TSX: HBP.TO
Total Equity · Q3 FY2026 · quarter ended Apr 2026
Total equity turns positive
Q3 FY2026 total equity was CA$14.69M, compared with -CA$1.39M a year earlier. Over 3 fiscal years it compounded at +265.6% a year.
Context
- Total equity amounted to 68.7% of total assets at the end of Q3 FY2026, down 69.1 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +1156.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
CAD · from the balance sheet
- Latest · FY2025
- 15.59M CAD
- Year-over-year change
- +17417.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 15.59M | +17417.8% |
| FY2024 | 2024-07-31 | (90K) | +89.3% |
| FY2023 | 2023-07-31 | (844K) | -364.6% |
| FY2022 | 2022-07-31 | 319K | +122.9% |
| FY2021 | 2021-07-31 | (1.39M) | — |
Total Equity vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1156.8% is the highest of 5, against a peer median of +45.5%.
- Total equity amounts to 68.7% of total assets for HBP.TO, versus a peer median of 85.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $70.71M USD | +69.7% | +101.9% | 93.9% |
| Mar 2026 | $58.61M USD | -12.3% | -21.1% | 44.7% | |
| Mar 2026 | CA$24.2M CAD | +37.6% | -30.0% | 77.1% | |
| Apr 2026 | CA$14.69M CAD | +1156.8% | +265.6% | 68.7% | |
| Apr 2026 | -CA$9.64M CAD | +53.3% | — | 628.3% | |
| Peer median (excluding HBP.TO) | — | +45.5% | -21.1% | 85.5% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.